1. Market Research
  2. > Healthcare Market Trends
  3. > 2014 Life Sciences Outlook in Turkey : Rapid Economic Development and Healthcare Reforms Set the Stage for the Future

Executive Summary

•The purpose of this study is to analyze the Turkish life sciences market, which includes the pharmaceuticals segment and the clinical diagnostics segment. In 2013, the life sciences market revenue in Turkey was valued at $x billion, growing at x% from 2012 to 2013.
•Rapid economic growth and the healthcare transformation program have generated a significant increase in healthcare expenditure between 2003 and 2011 in Turkey. The national healthcare expenditure of Turkey grew from $xbillion in 2006 to $x billion in 2013, registering a strong year-over-year (YOY) growth of x% during this period. The life sciences market in Turkey will witness more growth than mature markets such as those in the United States, Japan, and Europe.
•Rapid socio-economic development in Turkey has resulted in an increasing trend in non-communicable diseases such as coronary diseases, cancer, diabetes, hypertension, obesity, and chronic obstructive pulmonary diseases. In 2012, coronary diseases, cancer, and respiratory diseases accounted for more than x% of the hospital deaths in Turkey.
•In 2003, a series of changes and innovations was implemented to qualify the health services provision in accordance with modern standards and to render it more efficient, effective, and accessible through the Health Transformation Program (HTP) by the fifty-ninth government.
•The pharmaceuticals segment is the 14th largest worldwide and the 6th largest in Europe. This segment was valued at $x billion in 2013 and is expected to grow at a compound annual growth rate (CAGR) of x%, reaching $xbillion in 2018. Biotechnology-based drugs, diabetes, respiratory, and oncology drugs will exert the highest growth rates in the segment.
•The clinical diagnostics segment was valued at $x billion in 2013 and is expected to grow to at a CAGR of x%, reaching $xbillion by 2018.
•Following the centralization of the x former social security institutes (SSI) into a single SSI called Sosyal Guvenlik Kurumu (SGK), the social security system in Turkey underwent a significant transformation, resulting in a faster and more efficient health coverage system. Currently, % of Turkey’s total population is covered by the SGK.
•Turkey’s pharmaceuticals segment is dominated by international companies that constituted a combined share of x% in 2012. Local manufacturers, including Abdi Ibrahim (x% market share) and Bilim Ilac (x% market share), were among the top x pharmaceutical companies in Turkey.
•Because of huge capital investments and long research periods, Turkey does not conduct new molecule research. Research is mainly conducted on improving products and new formulations.

Study Scope

•This study provides an overview of the life sciences market in Turkey and its various therapeutic segments and product classes.
•For this research, life sciences market covers xmain segments: pharmaceuticals and clinical diagnostics.
•For the purpose of this research, the pharmaceuticals segment includes both drugs (small molecules) and biotechnology-based products (large molecules).
•In addition to market size and revenue forecast, detailed segment analysis has been provided for the pharmaceuticals segment with respect to investment trends, government reforms, regulatory policies, market shares, and key stakeholders.
•For the clinical diagnostics segment, top-line numbers and revenue forecasts have been provided.
•Revenues from medical devices and the private health care services segment are not included in this study.
•Other advanced medical technologies such as imaging, vital signs monitoring, and other tools used to diagnose and monitor patient conditions are not covered in this study.

Table Of Contents

2014 Life Sciences Outlook in Turkey : Rapid Economic Development and Healthcare Reforms Set the Stage for the Future
Executive Summary
Study Scope and Market Overview
Macroeconomic Overview of the Turkish Pharmaceutical Industry
Demographics and Disease Burden
Analysis of the Turkish Pharmaceuticals Segment
Mergers and Acquisitions and Investment Trends—Are You Putting Your Money in the Right Markets?
Government Initiatives to Foster Research and Development and Innovation
Pharmaceuticals Segment Value Chain—Key Stakeholders Influencing Sales and Production
Regulatory Environment—An Integral Part of Any Healthcare Conversation
Analysis of the Turkish Clinical Diagnostics Segment
Turkey to Emerge as the Regional (MENA) Life Sciences Capital—Government's Vision 2023
The Frost and Sullivan Story

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
India Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monitorin

India Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monitorin

  • $ 5995
  • Industry report
  • November 2016
  • by Global Data

India Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical ...

Canada Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monitori

Canada Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monitori

  • $ 5995
  • Industry report
  • October 2016
  • by Global Data

Canada Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical ...

United States Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient M

United States Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient M

  • $ 5995
  • Industry report
  • November 2016
  • by Global Data

United States Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Mi ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.